TerrAscend (TSNDF) Non Operating Investment Income (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Non Operating Investment Income of -$629000.0 for Q4 2025, down 2416.0% year-over-year from $27158.9 in Q4 2024, and down 62800.0% quarter-over-quarter from -$1000.0 in Q3 2025.
TerrAscend (TSNDF) Non Operating Investment Income (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Non Operating Investment Income for 5 consecutive years, with -$629000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Investment Income fell 2416.0% year-over-year to -$629000.0; the TTM figure through Mar 2026 stood at -$623000.0 (up 36.43% YoY), while the FY2025 annual figure was -$1.4 million, down 473.53% from the prior year.
- Non Operating Investment Income retreated to -$629000.0 in Q4 2025 per TSNDF's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $6.0 million in Q2 2021 and bottomed at -$1.7 million in Q2 2023.
- Historically, Non Operating Investment Income has averaged $126750.0 across 5 years, with a median of -$15000.0 in 2023.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income surged 380.0% — and 2025, when it tumbled 2416.0%.
- TerrAscend's Non Operating Investment Income stood at $6.0 million in 2021, then plunged by 99.23% to $46000.0 in 2022, then slumped by 619.57% to -$239000.0 in 2023, then jumped by 89.54% to -$25000.0 in 2024, then sank by 2416.0% to -$629000.0 in 2025.
- Business Quant data shows TSNDF's Non Operating Investment Income at -$629000.0 in Q4 2025, -$1000.0 in Q3 2025, and $7000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | TerrAscend | 197.99 Mn | 155.88 Mn | 36.25 Mn | -271,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -271,000.00 |
| Jun 30, 2026 | -271,000.00 |
| Dec 31, 2025 | -629,000.00 |
| Dec 31, 2025 | -629,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | -742,000.00 |
| Mar 31, 2025 | -742,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | -227,000.00 |
| Jun 30, 2024 | -227,000.00 |
| Dec 31, 2023 | -239,000.00 |
| Dec 31, 2023 | -239,000.00 |
| Sep 30, 2023 | -5,000.00 |
| Sep 30, 2023 | -5,000.00 |